Chikungunya virus vaccine - Takeda
Alternative Names: CHIKV - InviragenLatest Information Update: 23 Jun 2015
At a glance
- Originator SingVax
- Developer Takeda Pharmaceuticals USA
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chikungunya virus infections
Most Recent Events
- 23 Jun 2015 No recent reports of development identified - Phase-II for Chikungunya virus infections in USA (Parenteral)
- 31 May 2013 Inviragen has been acquired by Takeda Pharmaceuticals USA
- 27 Jan 2011 Inviragen and Duke-National University of Singapore Graduate Medical School agree to co-develop infectious disease vaccines (including chikungunya virus vaccine) in Singapore